"Bad CME" Program May Be Developed By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency asks physicians to report instances of off-label promotion made during continuing medical education classes.
You may also be interested in...
Can Bad Ad Program's Light Penetrate Murky CME, Clinical Trial Practices?
The "Bad Ad" program already has proven to be a great success in motivating health care providers to report well-known forms of false or misleading drug promotion, such as ads that overstate efficacy and minimize risks, but can it help address more subtle and difficult-to-detect forms of questionable drug promotion, such as those that are hidden in drugmakers' support of professional education and clinical trials?
Can Bad Ad Program's Light Penetrate Murky CME, Clinical Trial Practices?
The "Bad Ad" program already has proven to be a great success in motivating health care providers to report well-known forms of false or misleading drug promotion, such as ads that overstate efficacy and minimize risks, but can it help address more subtle and difficult-to-detect forms of questionable drug promotion, such as those that are hidden in drugmakers' support of professional education and clinical trials?
DDMAC To Cornerstone: Zyflo CR Promotions Need Current Safety Labeling
An FDA advertising violation letter for Cornerstone Therapeutics' asthma therapy Zyflo CR should serve to remind industry that providing outdated safety labeling with promotions is a sure way to draw the agency's regulatory scrutiny